Hyperoside attenuates NASH-associated liver fibrosis by modulating Flot2/TLR4 signaling and pyroptosis
Hyperoside mitigates NASH-driven hepatic fibrosis by specifically targeting Flot2 to block TLR4/NLRP3-mediated pyroptosis in hepatic stellate cells. This study not only identifies Flot2 as a novel therapeutic target but also provides a pharmacological framework for developing anti-fibrotic agents.
Authors
- Jian Qin (ORCID: https://orcid.org/0000-0002-5225-6169)
- Peng Huang (ORCID: https://orcid.org/0000-0001-9872-2834)
- Tingying Zhang (ORCID: https://orcid.org/0000-0001-5973-5333)
- Jianguo Hu (ORCID: https://orcid.org/0000-0002-9832-6951)
- Zhiling Li (ORCID: https://orcid.org/0000-0001-6579-7397)
- Lang Qin (ORCID: https://orcid.org/0000-0002-6135-7471)
- Taoli Liu (ORCID: https://orcid.org/0000-0002-7156-0238)
- Li Zhang (ORCID: https://orcid.org/0000-0002-3919-3247)
- Yunling Zhu
- Kaixuan Zeng
Institutions
- Sun Yat-sen University (CN)
Publication Details
- Journal
- International Immunopharmacology
- Published
- 2025-12-17
- DOI
- https://doi.org/10.1016/j.intimp.2025.116007
- Primary Topic
- Liver physiology and pathology
- Type
- article
- Field-Weighted Citation Impact
- 0.00